CM Treatment for Alcohol Dependence Using New Technology

UConn Health

Status: Completed

Conditions: Contingency Management; Alcohol Use Disorder

Treatments: Behavioral: prize contingency management for attending treatment; Behavioral: usual care

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT02143037

P60AA003510 (U.S. NIH Grant/Contract)

13-040-2

Details and patient eligibility

About

Contingency management (CM) is highly efficacious for reducing substance use, and recent data suggest that reinforcing attendance at treatment can significantly improve treatment outcomes. Importantly, CM interventions that reinforce attendance are more likely to be adopted clinically than those that reinforce abstinence. Having objective indicators of drinking outcomes, nevertheless, is critical for quantifying the benefits of attendance-based CM treatment in alcohol abusing populations. New technology is now available to gauge alcohol use in patients' natural environments. The Secure Continuous Remote Alcohol Monitor (SCRAMx®) continuously monitors alcohol consumption 24 hours a day. As such, it may be ideal for objective evaluation of alcohol consumption during treatment intervention studies, including those that involve CM.

In this study, 114 patients participating in community based outpatient treatment programs for alcohol use disorders will wear SCRAMx for a 12-week period. They will be randomized to standard care or standard care plus CM, with reinforcement contingent upon attendance at treatment. The investigators will assess treatment attendance and alcohol use via SCRAMx and self reports. The investigators expect that patients randomized to the CM intervention will remain in treatment longer and show reductions in both SCRAMx assessed and self reported drinking days relative to those randomized to standard care.

Enrollment: 114 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18 years or older
• current diagnosis of alcohol use disorder
• able to pass an informed consent quiz
• agree to wear a SCRAMx monitor for 12 weeks
• have a standard, SCRAMx compatible phone line in their home or agree to attend the clinic at least every other week for data downloads
• agree to sign an off-campus property transfer form and return SCRAMx equipment in 12 weeks

Exclusion criteria

• serious, uncontrolled psychiatric illness
• in recovery from pathological gambling
• unstable address
• intend to participate in activities incompatible with SCRAMx in the next 3 months
• are wearing SCRAMx for legal purposes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

114 participants in 2 patient groups

Control Group

Active Comparator group

Description:

usual care

Treatment:

Behavioral: usual care

Experimental Group

Experimental group

Description:

usual care plus prize contingency management for attending treatment

Treatment:

Behavioral: usual care

Behavioral: prize contingency management for attending treatment